Genetic Signatures TechInvest Magazine interview – August 2023
Genetic Signatures’ CEO, Dr John Melki was recently interviewed by David Tasker, Managing Director of Chapter One Advisors for TechInvest Magazine.
Read MoreGenetic Signatures Investor Presentation – TechKnow 2023
Genetic Signatures’ CEO- Dr. John Melki speaking at TechKnow Invest Roadshow which was held in Queensland and Melbourne Australia August 2023
Read MoreInvestor Presentation – Finance Network
Genetic Signatures Investor Presentation – TechKnow 2022
Genetic Signatures’ CEO- Dr. John Melki speaking at TechKnow Invest Roadshow- November 2022
Read MoreGenetic Signatures’ CEO, John Melki, talks with Nadine Blayney from AusBiz
Genetic Signatures’ CEO Dr John Melki was recently interviewed by Nadine Blayney from AusBiz about the Company’s unique 3base® technology, its advantages for detecting infectious diseases, the development pipeline, revenue sources, and plans for further investment and expansion in key international markets.
Read MoreSydPath Supports NSW COVID-19 Outbreak with Genetic Signatures’ Testing Technology
Channel 9 interviews our customer SydPath, taking a look at their increased testing capabilities in response to the COVID-19 outbreak in NSW, implementing our high-throughput testing technology for respiratory infection
Read MoreJohn Melki speaking at ASX Small and Mid-Cap Conference
Genetic Signatures’ CEO- Dr. John Melki speaking at ASX Small and Mid-Cap Conference held in Sydney Australia September 2018
Read More